Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial

Background: COVID-19 convalescent plasma (CCP) is an important antiviral option for selected patients with COVID-19. Materials and Methods: In this open-label, phase 2, clinical trial conducted from 30 April 2020 till 10 May 2021 in the Republic of North Macedonia, we evaluated the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Grubovic Rastvorceva, Rada M., Useini, Sedula, Stevanovic, Milena, Demiri, Ilir, Petkovic, Elena, Franchini, Massimo, Focosi, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605182/
https://www.ncbi.nlm.nih.gov/pubmed/36295001
http://dx.doi.org/10.3390/life12101565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605182/
https://www.ncbi.nlm.nih.gov/pubmed/36295001
http://dx.doi.org/10.3390/life12101565

Ejemplares similares